Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation

2025/11/21 by Starace, Michela, Cedirian, Stephano, Rapparini, Luca +27
#610 Medicine &amp #health

paper · doi:10.5167/uzh-280306

Abstract

This retrospective case series compares vitiligo resulting from immune checkpoint inhibitor (ICI) therapy vs preexisting vitiligo among patients receiving ICI treatment for cancer.

Related

• B-Cell involvement in immune checkpoint inhibitor-induced lichen planus: A comparative analysis with non–drug-related lichen planus
• An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma
• Vitiligo: Mechanisms of Pathogenesis and Treatment
• Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study
• Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy